Dapagliflozin Exports from India to EU Grow 18% in Q2 2026 Driven by Demand Shift

Senior Supply Chain Intelligence Analyst

EXECUTIVE SUMMARY

Export volumes increase across key EU markets amid China supply constraints and inventory destocking, consolidating India's position in the SGLT2 supply chain.

What Happened

Indian dapagliflozin API and formulation exports to the European Union rose 18% quarter-on-quarter in Q2 2026, led by Germany, Spain and Poland. The gain reflects both genuine demand growth in the SGLT2 class and a structural shift away from Chinese supply amid environmental-compliance constraints at several upstream sites.

INTELLIGENCE LOCKED — TERMINAL ACCESS REQUIRED

You are viewing the public fact summary. The full ChemLifeIntel analysis — downstream buyer exposure mapping, alternative supplier identification, and 5-year compliance footprint for Dapagliflozin — is available exclusively to Terminal subscribers.

TERMINAL ACCESS

Unlock the full analysis

Used by procurement and regulatory teams at 40+ pharmaceutical companies

Supply Chain Impact

EU formulators are pre-positioning second-source supply ahead of upcoming exclusivity expiries. Indian producers with EU GMP-cleared lines stand to capture durable share; buyers without qualified Indian sources face the highest exposure if Chinese supply tightens further.

Outlook

Expect the India–EU SGLT2 corridor to remain firm through H2 2026. Spot pricing should stabilise as new Indian capacity clears inspection, narrowing the originator-to-generic cost gap.

CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE

2 min ago

Aurobindo Pharma Unit VII: FDA Issues Warning Letter Citing Data Integrity Failures Across Three API Lines

Inspection reveals repeated data integrity violations in analytical testing, resulting in OAI classification and an import alert that detains shipments without physical examination pending remediation.

REGULATORY INTELLIGENCE

10h ago

EMA Flags Nitrosamine Impurity Across Three Sartan Suppliers; Recall Scope Under Review

Affected lots span valsartan and losartan batches distributed across the EU and UK since Q4 2025, with recall scope and supplier remediation under active review.

ENTITY HUBS

Entities in this Brief